

US MEDICAL CANNABIS LICENSING DEAL. INVESTOR CALL WITH RHINOMED CEO AND CHAIRMAN

2 October, 2018. Melbourne, Australia. Melbourne based nasal respiratory company Rhinomed (ASX: RNO) is pleased to invite shareholders to an investor call with Rhinomed CEO Michael Johnson and Chairman Ron Dewhurst to discuss the licensing agreement with Colombia Care and answer investors questions (questions to be submitted per details provided below).

Investor call to be hosted Tuesday October 2, 2018 at 11.30am.

Investor Call details:

Rhinomed Investor Webinar on Tuesday October 2, 2018 11:30 AM AEST

Access details:

Registration for the call can be completed via the link below:

<https://attendee.gotowebinar.com/register/3947240540464473090>

Dial-In details:

Australia +61 2 8355 1054

United States +1 (415) 930-5229

Attendee Access Code: 572-134-258

Shareholders to email any questions prior to the call to warrick@nwrcommunications.com.au

Media Enquiries

Warrick Lace

+61 404 656 408

warrick@nwrcommunications.com.au

About Rhinomed Limited (ASX: RNO)

Rhinomed Limited is a Melbourne based technology firm with a focus on nasal, respiratory and breathing management technologies. Rhinomed is seeking to radically improve the way you breathe, sleep, maintain your health and take medication. The company is rapidly commercializing its platform and has brought two products to market that are now sold globally. For more information go to www.rhinomed.global